Patritumab  (Synonyms: Human Anti-ERBB3 Recombinant Antibody)

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors^[1].

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis^[1].
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells^[1].
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice^[1].
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1262787-83-6

Liquid

Colorless to light yellow

[Patritumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56.  [Content Brief]